Array BioPharma Inc. (NASDAQ:ARRY) was up 4.9% during trading on Monday . The stock traded as high as $3.41 and last traded at $3.40, with a volume of 1,188,725 shares. The stock had previously closed at $3.24.

Several equities research analysts have commented on ARRY shares. Jefferies Group reissued a “buy” rating on shares of Array BioPharma in a research report on Wednesday, May 4th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Array BioPharma in a report on Wednesday, May 4th. Leerink Swann reaffirmed a “buy” rating and issued a $6.00 target price on shares of Array BioPharma in a report on Thursday, May 5th. SunTrust Banks Inc. began coverage on shares of Array BioPharma in a report on Thursday, June 2nd. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Zacks Investment Research raised shares of Array BioPharma from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.50.

The company’s 50-day moving average price is $3.73 and its 200 day moving average price is $3.25. The company’s market cap is $493.43 million.

Array BioPharma (NASDAQ:ARRY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.02. The business had revenue of $43.20 million for the quarter, compared to analyst estimates of $41.51 million. Array BioPharma’s quarterly revenue was up 251.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) earnings per share. Equities research analysts forecast that Array BioPharma Inc. will post ($0.68) earnings per share for the current year.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.